Literature DB >> 20421765

Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.

Egbert F Smit1, Anne-Marie C Dingemans, Frederik B Thunnissen, Monique M Hochstenbach, Robert-Jan van Suylen, Pieter E Postmus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20421765     DOI： 10.1097/JTO.0b013e3181d86ebf

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  15 in total

1.  Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?

Authors:  Giulio Metro; Vincenzo Minotti; Lucio Crinò
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

Review 2.  Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.

Authors:  Eamon M Berge; Robert C Doebele
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

3.  A 2-stage phase II design with direct assignment option in stage II for initial marker validation.

Authors:  Ming-Wen An; Sumithra J Mandrekar; Daniel J Sargent
Journal:  Clin Cancer Res       Date:  2012-06-14       Impact factor: 12.531

4.  Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.

Authors:  Ronan J Kelly; Arun Rajan; Jeremy Force; Ariel Lopez-Chavez; Corrine Keen; Liang Cao; Yunkai Yu; Peter Choyke; Baris Turkbey; Mark Raffeld; Liqiang Xi; Seth M Steinberg; John J Wright; Shivaani Kummar; Martin Gutierrez; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2011-01-11       Impact factor: 12.531

5.  Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.

Authors:  Vladimir Beljanski; Clayton S Lewis; Charles D Smith
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

Review 6.  Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.

Authors:  Pascale Tomasini; Preet Walia; Catherine Labbe; Kevin Jao; Natasha B Leighl
Journal:  Oncologist       Date:  2016-11-02

7.  The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.

Authors:  Juan Wang; Shumei Ma; Xiuhua Chen; Sanqi Zhang; Zhiyong Wang; Qibing Mei
Journal:  Invest New Drugs       Date:  2018-11-19       Impact factor: 3.850

8.  A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.

Authors:  Heather A Wakelee; Ju-Whei Lee; Nasser H Hanna; Anne M Traynor; David P Carbone; Joan H Schiller
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

9.  Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival.

Authors:  Abidin Geles; Ulrike Gruber-Moesenbacher; Franz Quehenberger; Claudia Manzl; Mohamed Al Effah; Elisabeth Grygar; Freyja Juettner-Smolle; Helmut H Popper
Journal:  Virchows Arch       Date:  2015-10-08       Impact factor: 4.064

10.  Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.

Authors:  George R Blumenschein; Pierre Saintigny; Suyu Liu; Edward S Kim; Anne S Tsao; Roy S Herbst; Christine Alden; J Jack Lee; Ximing Tang; David J Stewart; Merrill S Kies; Frank V Fossella; Hai T Tran; L Mao; Marshall E Hicks; Jeremy Erasmus; Sanjay Gupta; Luc Girard; Michael Peyton; Lixia Diao; Jing Wang; Suzanne E Davis; John D Minna; Ignacio Wistuba; Waun K Hong; John V Heymach; Scott M Lippman
Journal:  Clin Cancer Res       Date:  2013-10-28       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.